Guidance for the Conduct and Reporting of Clinical Trials of Breast Milk Substitutes

Katharine Jarrold, Bartosz Helfer, Mona Eskander, Helen Crawley, Jillian Trabulsi, Laura E Caulfield, Gillian Duffy, Vanessa Garcia-Larsen, Deborah Hayward, Matthew Hyde, Suzan Jeffries, Mikael Knip, Jo Leonardi-Bee, Elizabeth Loder, Caroline J Lodge, Adrian J Lowe, William McGuire, David Osborn, Hildegard Przyrembel, Mary J RenfrewPaula Trumbo, John Warner, Barbara Schneeman, Robert J Boyle

Research output: Contribution to journalArticlepeer-review


Importance: Breast milk substitutes (BMS) are important nutritional products evaluated in clinical trials. Concerns have been raised about the risk of bias in BMS trials, the reliability of claims that arise from such trials, and the potential for BMS trials to undermine breastfeeding in trial participants. Existing clinical trial guidance does not fully address issues specific to BMS trials.

Objectives: To establish new methodological criteria to guide the design, conduct, analysis, and reporting of BMS trials and to support clinical trialists designing and undertaking BMS trials, editors and peer reviewers assessing trial reports for publication, and regulators evaluating the safety, nutritional adequacy, and efficacy of BMS products.

Design, Setting, and Participants: A modified Delphi method was conducted, involving 3 rounds of anonymous questionnaires and a face-to-face consensus meeting between January 1 and October 24, 2018. Participants were 23 experts in BMS trials, BMS regulation, trial methods, breastfeeding support, infant feeding research, and medical publishing, and were affiliated with institutions across Europe, North America, and Australasia. Guidance development was supported by an industry consultation, analysis of methodological issues in a sample of published BMS trials, and consultations with BMS trial participants and a research ethics committee.

Results: An initial 73 criteria, derived from the literature, were sent to the experts. The final consensus guidance contains 54 essential criteria and 4 recommended criteria. An 18-point checklist summarizes the criteria that are specific to BMS trials. Key themes emphasized in the guidance are research integrity and transparency of reporting, supporting breastfeeding in trial participants, accurate description of trial interventions, and use of valid and meaningful outcome measures.

Conclusions and Relevance: Implementation of this guidance should enhance the quality and validity of BMS trials, protect BMS trial participants, and better inform the infant nutrition community about BMS products.

Original languageEnglish
JournalJAMA pediatrics
Early online date11 May 2020
Publication statusE-pub ahead of print - 11 May 2020

Bibliographical note

© 2020 Jarrold K et al.

Cite this